n=1 Intervention Ethics Checklist

Why an n=1 intervention needs its own ethics checklist

An n=1 intervention is a personalized approach designed around a single person’s needs, context, and outcomes. That can be powerful. It can also create ethical risk when your plan relies on limited evidence, tight timelines, and real-world constraints. In practice, the ethical challenge is rarely “should we try?” The challenge is “how do we try responsibly, transparently, and with safeguards that match the risk?”

This n=1 intervention ethics checklist is built for the moments that usually get overlooked: deciding what counts as appropriate benefit, protecting privacy when data is collected frequently, ensuring consent is meaningful even when urgency is high, and defining what you will do if things go wrong. Use it as a structured way to think through decisions before you begin—and to keep checking as conditions change.

Define the intervention precisely before you assess ethics

Ethics work starts with clarity. If you cannot describe what you are doing, why you are doing it, and what “success” looks like, you cannot judge proportionality, feasibility, or harm reduction.

Write a one-page intervention brief

• Target problem: What specific issue are you trying to address (symptoms, functional limitation, behavior, risk exposure)?
• Population context: What are the person’s relevant circumstances (age range, comorbidities, living situation, communication needs)?
• Intervention components: What actions will be taken (training sessions, medication changes, behavior supports, coaching, environmental modifications)?
• Intensity and timeframe: How often and for how long (for example, 3 sessions per week for 6 weeks; nightly monitoring for 14 days; a medication titration over 2–4 weeks)?
• Outcome measures: What you will measure to determine whether the intervention is working (and how often).
• Stop or pause criteria: What would trigger stopping, pausing, or escalation to a higher level of care.

When you define the intervention this way, ethical review becomes concrete. You can more easily evaluate whether the planned effort is proportionate and whether consent is aligned with what will actually happen.

Consent that is meaningful, specific, and revisited

In n=1 work, consent cannot be a one-time formality. The ethical requirement is that the person understands the plan, the uncertainties, the risks, and the alternatives in language they can use.

Check consent quality against these standards

• Specificity: Does your consent discussion clearly cover the exact intervention components and the expected duration (e.g., “for 6 weeks, with weekly check-ins”)?
• Uncertainty: Have you explained what is known versus unknown for this specific person (not just general evidence)?
• Risks and burdens: Are you transparent about foreseeable harms and time costs (travel, monitoring effort, side effects, emotional burden)?
• Alternatives: Have you discussed other reasonable options, including “no change” or standard care?
• Right to withdraw: Can the person stop participation without punitive consequences?
• Re-consent points: Will you revisit consent if the intervention changes, if new risks emerge, or if monitoring intensity increases?

Account for capacity and communication

If decision-making capacity may be affected by illness, medication effects, cognitive impairment, intoxication, or stress, you need an additional layer of care. Use appropriate communication supports (plain language, interpreter services, teach-back). If consent is not fully autonomous, involve appropriate safeguards consistent with local law and professional standards.

Practical example: Imagine you are coordinating an n=1 behavioral intervention for a person with severe anxiety. The plan includes weekly exposure sessions and daily symptom tracking. If the person’s anxiety worsens during the first 7 days, you should reassess whether they still understand and agree to the exposure schedule. Re-consent is not about paperwork—it’s about ensuring the person’s agreement remains meaningful under changing conditions.

Risk proportionality: match safeguards to potential harm

Ethics in n=1 interventions often fails when risk is treated as an afterthought. Because you are focusing on one person, harms can be more immediate and harder to “average out.” Your checklist must therefore include a structured risk proportionality review.

Identify foreseeable risks and categorize them

• Physical risks: Side effects, injury risk, medication interactions, fatigue, sleep disruption.
• Psychological risks: Increased distress, stigma, loss of autonomy, triggering events.
• Social risks: Disclosure risks, conflicts with family or workplace, changes in relationships.
• Economic risks: Costs of participation, missed work, transportation burdens.
• Data risks: Privacy breaches, re-identification, unintended sharing.

Set monitoring intensity based on risk

Use the person’s risk profile to decide how frequently you monitor. For example, if a medication titration is planned, you might require checks within 24–72 hours after a dose change, then weekly thereafter. If you are using frequent self-monitoring (daily), you should also define what happens when signals worsen.

Rule of thumb: The higher the potential severity of harm, the more “tight” your safety net should be—faster escalation pathways, clearer stop criteria, and more frequent reassessment.

Data governance and privacy for single-person monitoring

n=1 interventions frequently rely on repeated measurements—daily symptom scores, wearable data, session notes, or real-time tracking. That creates privacy and data governance challenges that may not be obvious in standard care.

Clarify data types and the purpose of collection

• Data categories: What data will you collect (health metrics, location, communications, biometrics, photos, free-text notes)?
• Purpose limitation: Are you collecting data only to guide the intervention, or also for secondary uses (research, quality improvement)?
• Minimum necessary: Could you achieve the safety and outcome goals with less data?

Protect privacy in storage, access, and sharing

• Access control: Limit who can view raw data. Define roles and permissions.
• Encryption and secure storage: Ensure data is stored securely and transmitted safely.
• Retention limits: Set a timeframe for how long identifiable data will be kept (for example, 12 months after intervention completion unless required longer by policy).
• De-identification: If data is used beyond immediate care, consider de-identification and document the approach.
• Sharing rules: Specify when data may be shared with family, caregivers, or other professionals—and require consent where appropriate.

Be careful with consumer devices and “helpful” apps

Many people use consumer health technologies (sleep trackers, activity monitors, symptom logging apps). In an n=1 context, you should treat these as data sources with ethical implications. Confirm what you can access, how reliably it reflects the intended outcome, and whether the device platform has policies that could expose the person’s information. If you plan to import data into clinical records, ensure the workflow is secure and consented.

Outcome measurement that is valid, fair, and not misleading

Ethics requires that you measure outcomes honestly and interpret them responsibly. In an n=1 design, it’s easy to over-attribute changes to the intervention, especially with short timelines or fluctuating conditions.

Choose outcomes that match the goal

• Relevance: Are outcomes meaningful to the person’s daily life, not just easy to measure?
• Specificity: Are measures tied to the intervention mechanism (e.g., exposure-related anxiety symptoms rather than unrelated metrics)?
• Frequency: Is measurement frequent enough to detect meaningful change without creating excessive burden?
• Baseline: Do you have a baseline period (commonly 1–2 weeks, or longer if symptoms are slow to shift)?

Plan for confounders and regression to the mean

Symptoms and behaviors often fluctuate naturally. If you start an intervention during a temporary improvement, you may wrongly conclude it “worked.” Conversely, starting during a worsening phase can make the intervention look ineffective. Ethical practice includes documenting context changes (sleep changes, major life events, medication changes, illness) and interpreting results with those factors in mind.

Define decision rules ahead of time

Before you begin, specify how you will decide whether to continue, modify, or stop. For example, you might decide to adjust the plan if symptom scores worsen for 3 consecutive days or if a safety threshold is crossed. Decision rules reduce bias and help keep the process fair and consistent.

Clinical and operational safeguards: escalation, supervision, and documentation

Even when you design carefully, real-world situations change quickly. Ethical n=1 practice therefore depends on operational safeguards: who is responsible, how quickly you respond, and how you document key decisions.

Establish escalation pathways

• Who to contact: Define the responsible clinician or program lead, and backup contacts.
• Timeframes: Set expected response times (for example, same day for urgent risk signals; within 24 hours for non-urgent concerns).
• When to escalate: Use stop or escalation criteria tied to risk (suicidal ideation, severe side effects, medical deterioration, unsafe behaviors).
• Emergency guidance: Ensure the person knows what to do in emergencies.

Clarify roles across the care team

In n=1 work, it’s common for responsibilities to blur between the person, caregivers, and multiple professionals. Document who does what: who reviews data, who adjusts the plan, who communicates results, and who signs off on changes that increase risk.

Document decisions to support transparency

• Baseline rationale: Why you selected the start date and baseline duration.
• Consent updates: When re-consent occurred and why.
• Safety decisions: What risk signals triggered action.
• Outcome interpretation: How you interpreted results and what you did next.

Documentation is not a bureaucratic exercise. It protects the person and supports accountability.

Ethical boundaries for experimentation, innovation, and off-label use

Sometimes n=1 interventions are used to address situations where standard options have failed. That can be appropriate. But it increases ethical pressure to distinguish careful individualized care from experimentation without appropriate safeguards.

Determine whether this is clinical care or research-like activity

• Clinical care orientation: The intervention is intended to benefit the person based on professional judgment.
• Research-like orientation: The intervention primarily tests a hypothesis, uses protocols beyond standard care, or collects data for generalizable knowledge.

If your activities are research-like, additional oversight (such as institutional review processes) may be required depending on jurisdiction and setting. Don’t assume “it’s only one person” makes oversight unnecessary.

Off-label or nonstandard interventions require extra clarity

If you are considering off-label medication use, novel device-based approaches, or unusual dosing strategies, your ethical checklist should include:

• Rationale: Why standard options are insufficient for this person.
• Evidence summary: What evidence exists and its limitations.
• Risk assessment: How risks are mitigated and monitored.
• Consent specificity: The person understands this is not standard and why.

Real-world scenario walkthrough: an n=1 safety-first plan

Consider a practical scenario: you’re supporting an adult with migraine who reports frequent attacks and wants an individualized adjustment plan. The n=1 intervention includes a 2-week baseline tracking period, then a 6-week schedule combining medication timing adjustments, trigger management coaching, and a daily symptom diary.

Here’s how the ethics checklist applies in practice:

• Consent: You explain that the plan is individualized and that response is uncertain. You cover potential medication side effects and the possibility of needing a change if attacks increase.
• Risk proportionality: Because medication changes can affect safety, you set a threshold for escalation—such as severe side effects or a rapid increase in attack frequency. You also plan for urgent contact within 24 hours if thresholds are crossed.
• Data governance: The person uses a diary app and optionally a wearable. You confirm what data will be shared with the clinician, how it will be stored, and how long it will be retained after the 6-week period.
• Outcome measurement: You define primary outcomes (number of migraine days per 28 days; pain severity average) and secondary outcomes (sleep quality, medication use frequency). You include baseline context so day-to-day fluctuations don’t mislead decisions.
• Decision rules: You predefine what happens if migraine days worsen for 3 consecutive weeks or if safety thresholds are triggered—pause the plan and reassess.
• Documentation: You record baseline rationale, consent updates, safety actions, and the final decision at the end of 6 weeks.

This scenario shows the core ethical principle: your safeguards and decision rules are designed to match the uncertainty and potential harm of the intervention, not just the desire to improve outcomes.

Prevention and follow-through: what to do after the intervention

Ethics doesn’t end when the planned period ends. n=1 interventions can leave people dependent on a monitoring routine or uncertain about next steps. Your checklist should include a responsible wrap-up.

Plan the transition

• Step-down strategy: If monitoring was intensive (daily tracking), define how you reduce frequency.
• Long-term safety: Ensure stop criteria and escalation pathways remain accessible even after the main intervention ends.
• Outcome communication: Explain results in plain language, including what improved, what did not, and what you believe the reasons might be.

Review ethics performance and update the protocol

After completion, review what went well and what created ethical friction. Examples include consent confusion, unclear escalation, excessive burden from monitoring, or data access problems. Use that review to refine future n=1 plans so the ethical process improves over time.

n=1 intervention ethics checklist (use this as a pre-start and ongoing review)

Use the checklist below twice: once before starting, and again at key points (midpoint, after any safety signal, and at conclusion).

• Intervention clarity: Can you describe the intervention components, timeframe, and stop criteria in specific terms?
• Consent quality: Did you obtain meaningful consent with uncertainty, risks, burdens, and alternatives clearly explained?
• Re-consent triggers: Have you defined when consent will be revisited (plan changes, risk changes, increased monitoring)?
• Capacity and communication: Have you assessed decision-making capacity and used appropriate communication supports?
• Risk assessment: Have you identified physical, psychological, social, economic, and data risks?
• Proportional safeguards: Do your monitoring frequency and escalation timelines match the severity of potential harm?
• Escalation pathways: Are emergency steps and response time expectations clearly defined?
• Outcome validity: Are outcome measures relevant, specific, and interpreted with baseline context and confounders in mind?
• Decision rules: Did you predefine continuation, modification, and stopping criteria?
• Data governance: Are you collecting the minimum necessary data, with secure storage, access control, retention limits, and clear sharing rules?
• Device/app considerations: If using consumer tools, have you addressed privacy, data reliability, and secure workflows?
• Documentation: Did you record baseline rationale, consent updates, safety actions, and outcome interpretation?
• Post-intervention transition: Is there a plan for step-down, ongoing safety, and clear next steps?

Summary: ethical n=1 practice is about clarity, proportional safeguards, and accountable follow-through

An n=1 intervention can be ethically sound when you treat it as a structured decision process rather than an informal trial. Your strongest safeguards come from defining the intervention precisely, obtaining meaningful consent that you revisit when conditions change, matching monitoring and escalation to risk, and governing data responsibly. Finally, ethical follow-through requires a transition plan and documentation that supports accountability.

If you apply this n=1 intervention ethics checklist consistently—before starting and whenever risk or uncertainty shifts—you reduce the chance that good intentions lead to avoidable harm.

07.12.2025. 03:27